Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
33.49
+0.55 (1.67%)
Aug 5, 2026, 9:33 AM EDT - Market open
Viking Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 125.75 | 165.81 | 26.68 | 55.52 | 36.63 | 26.37 |
Short-Term Investments | 375.91 | 539.93 | 875.94 | 306.56 | 118.85 | 175.73 |
Cash & Short-Term Investments | 501.66 | 705.74 | 902.61 | 362.08 | 155.49 | 202.1 |
Cash Growth | -37.89% | -21.81% | 149.29% | 132.87% | -23.07% | -18.63% |
Other Current Assets | 16.11 | 9.86 | 4.6 | 5.15 | 11.56 | 8.43 |
Total Current Assets | 517.56 | 715.6 | 907.22 | 367.23 | 167.04 | 210.53 |
Net Property, Plant & Equipment | 4.01 | 0.09 | 1 | 1.13 | 1.42 | 0.03 |
Other Long-Term Assets | 0.11 | 0.05 | 0.1 | 0.14 | 0.07 | 0.11 |
Total Assets | 521.9 | 715.73 | 908.32 | 368.49 | 168.53 | 210.66 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 69.01 | 53.25 | 9.81 | 7.51 | 8.53 | 1.44 |
Accrued Expenses | 40.48 | 23.28 | 17.11 | 11.3 | 13.11 | 7.31 |
Current Portion of Leases | 0.16 | 0.14 | 0.49 | 0.32 | 0.3 | 0.03 |
Total Current Liabilities | 109.66 | 76.67 | 27.41 | 19.14 | 21.95 | 8.78 |
Long-Term Leases | 3.93 | - | 0.63 | 0.94 | 1.26 | - |
Total Long-Term Liabilities | 3.93 | - | 0.63 | 0.94 | 1.26 | - |
Total Liabilities | 113.58 | 76.67 | 28.04 | 20.07 | 23.21 | 8.78 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | - | - | - | -6.8 | -6.8 | - |
Additional Paid-in Capital | 1,543 | 1,486 | 1,369 | 733.55 | 445.27 | 425.61 |
Accumulated Other Comprehensive Income | -1.15 | 0.38 | -0.79 | -0.39 | -1.1 | -0.55 |
Retained Earnings | -1,134 | -847.55 | -487.91 | -377.94 | -292.05 | -223.18 |
Shareholders' Equity | 408.32 | 639.06 | 880.28 | 348.42 | 145.32 | 201.88 |
Total Liabilities & Equity | 521.9 | 715.73 | 908.32 | 368.49 | 168.53 | 210.66 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 4.09 | 0.14 | 1.12 | 1.26 | 1.56 | 0.03 |
Net Cash (Debt) | 497.58 | 705.6 | 901.49 | 360.82 | 153.92 | 202.07 |
Net Cash Growth | -38.33% | -21.73% | 149.85% | 134.42% | -23.83% | -18.53% |
Net Cash Per Share | 4.34 | 6.26 | 8.27 | 3.82 | 2.00 | 2.62 |
Book Value | 408.32 | 639.06 | 880.28 | 348.42 | 145.32 | 201.88 |
Book Value Per Share | 3.56 | 5.67 | 8.07 | 3.69 | 1.89 | 2.62 |
Tangible Book Value | 408.32 | 639.06 | 880.28 | 348.42 | 145.32 | 201.88 |
Tangible Book Value Per Share | 3.56 | 5.67 | 8.07 | 3.69 | 1.89 | 2.62 |